ACNU Feasibility

View full report
GoodFarxiga is an oral SGLT2 inhibitor with mild common side effects but serious rare risks requiring clinician monitoring, complex dosing based on kidney function, and careful use in special populations; misuse risk exists due to weight loss effects, though no abuse potential.

ACNU Feasibility Scorecard

Chart with 11 data points.
Farxiga
The chart has 1 X axis displaying categories.
The chart has 1 Y axis displaying ← Lower is Better!. Data ranges from 2 to 8.
End of interactive chart.